证券研究报告| 公司动态点评 2025 年 08 月 27 日 凯赛生物（688065.SH） 1H25 公司业绩同比增长，生物基聚酰胺项目持续推进-凯赛生物 2025 半年报点评 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 2,114 | 2,958 | 3,537 | 4,704 | 5,704 | | 增长率 yoy（%） | -13.4 | 39.9 | 19.6 | 33.0 | 21.2 | | 归母净利润（百万元） | 367 | 489 | 677 | 817 | 1,012 | | 增长率 yoy（%） | -33.8 | 33.4 | 38.4 | 20.7 | 24.0 | | ROE（%） | 2.8 | 3.1 | 4.6 | 5.3 | 6.2 | | EPS 最新摊薄（元） | 0.51 | 0.68 | 0.94 | 1.13 | 1.40 | | P/E（倍） | 105.7 | 79.3 | 57.3 | 47.5 | ...

凯赛生物（ [Table_StockNameRptType] 688065） 公司点评 25Q2 业绩持续增长，生物基 PA 商业化放量在即 | 投资评级：买入（维持） [Table_Rank] | | | --- | --- | | 报告日期： | 2025-08-25 | | [Table_BaseData] 收盘价（元） | 51.71 | | 近 12 个月最高/最低（元） | 56.98/32.48 | | 总股本（百万股） | 721 | | 流通股本（百万股） | 583 | | 流通股比例（%） | 80.88 | | 总市值（亿元） | 373 | | 流通市值（亿元） | 302 | [公司价格与沪深 Table_Chart] 300 走势比较 -15% 6% 27% 48% 69% 8/24 11/24 2/25 5/25 凯赛生物 沪深300 [Table_Author] 分析师：王强峰 执业证书号：S0010522110002 电话：13621792701 邮箱：wangqf@hazq.com 分析师：刘天其 执业证书号：S0010524080003 电话：17321190296 邮 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Insights - The company reported a revenue of 1.671 billion yuan for H1 2025, reflecting a year-on-year growth of 16% and a net profit of 309 million yuan, up 25% year-on-year [8] - The sales volume of long-chain dicarboxylic acids, particularly sebacic acid, reached a historical high, with the company maintaining a global leading position in this product line [8] - The company is actively building an ecosystem for bio-based polyamide and its composite materials, with several strategic partnerships and projects underway to enhance production capacity and market reach [8] Financial Data and Profit Forecast - Total revenue projections for 2025 are estimated at 3.539 billion yuan, with a year-on-year growth rate of 19.6% [7] - The forecasted net profit for 2025 is 648 million yuan, representing a year-on-year increase of 32.4% [7] - The company's gross margin for Q2 2025 was reported at 34.03%, showing a slight increase compared to previous periods [8]

Market Strategy - The market continues to rise with increased volume, as the Shenzhen Component Index and the ChiNext Index both break through the high points from October 8, 2024 [4][7] - The overall market sentiment is improving, with the total trading volume reaching 2.8 trillion yuan, an increase of over 500 billion yuan from the previous trading day [8][10] Industry Dynamics - In the first half of 2025, the mobile game advertising monetization trend in China shows that incentivized videos have become the preferred choice for developers, with platforms like Youmi and Pangle strengthening their positions [25][26] - The banking sector's total assets grew to 467.3 trillion yuan by the end of Q2 2025, a year-on-year increase of 7.9%, with large commercial banks seeing a 10.4% growth [28][29] - The New Tibet Railway is expected to start construction this year, with an estimated investment of over 400 billion yuan for the entire project [31][33] Company Tracking - Stone Technology (688169.SH) reported a 39.55% year-on-year decline in net profit for H1 2025, despite a revenue increase of 78.96% to 7.903 billion yuan [37] - Zhongjing Food (300908.SZ) experienced a 2.50% decrease in revenue for H1 2025, while net profit grew by 0.29% to 1.01 billion yuan [39] - Meihua Medical (301363.SZ) achieved a revenue of 733 million yuan in H1 2025, reflecting a 3.73% year-on-year growth, but net profit fell by 32.44% [41] - Ecovacs (603486.SH) reported a 60.84% increase in net profit for H1 2025, reaching 979 million yuan, with total revenue growing by 24.37% [43] - Kasei Bio (688065.SH) saw a 15.68% increase in revenue to 167 million yuan in H1 2025, with net profit rising by 24.74% [45] - Jiangyin Bank (002807.SZ) reported a 10.5% increase in revenue for H1 2025, with net profit growing by 16.6% [47]

Fundraising Overview - The company raised a total of RMB 5,560,621,023.10 from its initial public offering in 2019, after deducting underwriting and advisory fees, resulting in a net amount of RMB 5,279,993,815.60 [1] - In 2023, the company raised RMB 5,918,968,112.35 from a targeted issuance of A-shares, with a net amount of RMB 5,914,724,993.63 after deducting related fees [2] Fund Utilization and Balance - For the 2019 IPO, the net amount raised was RMB 529,407.39 million, with total project investments amounting to RMB 542,500.59 million, resulting in a balance of RMB 15,411.90 million as of the end of the reporting period [3] - In 2023, the net amount raised was RMB 591,750.40 million, with total project investments reaching RMB 592,079.80 million, indicating a balance of RMB 329.40 million [3] Fund Management Practices - The company has established a dedicated management system for the raised funds, adhering to relevant laws and regulations, and has implemented a special account storage system for the funds [6][10] - The company signed multiple tripartite supervision agreements with banks and underwriters to ensure proper management and usage of the raised funds [7][10] Fund Storage Status - As of June 30, 2025, the special accounts for the 2019 IPO have been fully utilized and closed [10] - The special accounts for the 2023 targeted issuance are also set to be closed following the completion of the relevant projects [11] Actual Use of Funds - The company has reported that the funds raised have been utilized in accordance with the planned investment projects, with detailed usage outlined in attached tables [12][15] - Any surplus funds from the projects have been permanently allocated to supplement working capital for daily operations [12][15]

Core Points - The annual general meeting of Shanghai Cathay Biotech Co., Ltd. is scheduled for June 27, 2025, at 14:00, combining on-site and online voting methods [3][4] - The company reported a significant increase in revenue and net profit for 2024, with total revenue reaching CNY 2,957.91 million, a 39.91% increase year-on-year, and net profit attributable to shareholders amounting to CNY 488.96 million, a 33.41% increase [16][32] - The company plans to distribute a cash dividend of CNY 4.00 per 10 shares, totaling CNY 287.58 million, based on the audited net profit for 2024 [8][9] Meeting Procedures - Attendees must register and confirm their attendance before the meeting starts, and they are required to present their shareholder certificates to enter the venue [2][3] - The meeting will include the election of monitors and counters, the presentation of the independent directors' report, and the discussion of various proposals [4][6][11] Financial Performance - The company achieved a net profit of CNY 488.96 million in 2024, with a significant increase in net profit excluding non-recurring gains and losses, which rose by 51.60% to CNY 464.73 million [16][32] - The total assets of the company reached CNY 19.02 billion, reflecting a stable financial position [32] Strategic Developments - The company has successfully introduced CNY 5.915 billion in funding through a directed issuance of shares to enhance its business development [18] - A strategic cooperation agreement was signed with Hefei Municipal Government and China Merchants Innovation Technology Group to establish a synthetic biological materials industry cluster [18][28] Governance and Compliance - The board of directors and the supervisory board have actively fulfilled their responsibilities, ensuring compliance with relevant laws and regulations [19][25] - The company has maintained a high standard of information disclosure, achieving an A-level rating for its disclosure practices in the Shanghai Stock Exchange [23][26]

【SynBioCon】 获 悉，4月21日晚间， 凯赛生物 发布2024年年度报告。报告期内， 公司实现营业收入29.58 亿元，比上年同期上升39.91%，实 现营业利润 5.52 亿元，比上年同期上升21.41%；归属于上市公司股东的净利润 4.89 亿元，比上年同期上升33.41% 。 | | | | | 单位:元 币种:人民币 | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 本期比上年 同期增减 | 2022年 | | | | | (%) | | | 营业收入 | 2, 957, 911, 554. 76 | 2, 114, 174, 868. 81 | 39. 91 | 2, 441, 103, 971. 54 | | 归属于上市公 司股东的净利 | 488, 961, 919. 11 | 366, 524, 351. 34 | 33. 41 | 553, 265, 973. 38 | | 润 | | | | | | 归属于上市公 司股东的扣除 | 464, 730, 541. 23 | 306, 551, 869. 92 | ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月21日晚间， 凯赛生物 发布2024年年度报告。报告期内，公司实现 营业收入29.58 亿元，比上年同期上升39.91% ， 实现营业利润 5.52 亿元，比上年 同期上升21.41% ；归属于上市公司股东的净利润 4.89 亿元，比上年同期上升33.41%。 | 单位 | | --- | | . | | 리 | | 市种 . | | 人民币 . | | | | | 本期比上年 | | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 同期增减 | 2022年 | | | | | (%) | | | 营业收入 | 2, 957, 911, 554. 76 | 2, 114, 174, 868. 81 | 39. 91 | 2, 441, 103, 971. 54 | | 归属于上市公 | | | | | | 司股东的净利 | 488, 961, 919. 11 | 366, 524, 3 ...

Core Insights - The company reported a revenue of 2.958 billion yuan in 2024, representing a year-on-year growth of 39.91%, and a net profit of 489 million yuan, up 33.41% year-on-year [2] - The company plans to distribute a cash dividend of 4.00 yuan per 10 shares to all shareholders [2] Group 1: Business Performance - The company maintains a global leading position in long-chain dicarboxylic acid products, with significant sales growth driven by technological advancements and market expansion [2][3] - The production capacity of bio-based caprylic acid has significantly increased since the project commenced in Q3 2022, leading to improved operational rates and market share [3] - The company successfully launched a 10,000-ton bio-based piperidine project at the end of 2024, which has begun generating sales [3] Group 2: Strategic Developments - The company has entered into a strategic cooperation agreement with the Hefei government and China Merchants Group to leverage their strengths in policy guidance, application scenario development, and biomanufacturing technology innovation [4] - A new company focused on composite materials manufacturing has been established, and projects are accelerating in Hefei, indicating the establishment of a comprehensive industrial chain for bio-based materials [4] Group 3: Research and Development - The company plans to focus on the development of the bio-based polyamide market in 2025, with a factory for bio-based polyamide modification and Bio-PPA CFRT under construction in Hefei [5] - Research and development expenses for 2024 amounted to 233 million yuan, a year-on-year increase of 23.38%, accounting for 7.89% of total revenue, with significant progress in various R&D projects [5]